Movatterモバイル変換


[0]ホーム

URL:


AU2001275437A1 - Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas - Google Patents

Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas

Info

Publication number
AU2001275437A1
AU2001275437A1AU2001275437AAU7543701AAU2001275437A1AU 2001275437 A1AU2001275437 A1AU 2001275437A1AU 2001275437 AAU2001275437 AAU 2001275437AAU 7543701 AAU7543701 AAU 7543701AAU 2001275437 A1AU2001275437 A1AU 2001275437A1
Authority
AU
Australia
Prior art keywords
ligands
bind
diagnosis
treatment
gene targets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275437A
Inventor
Cheryl Heard
Karen Mclachlan
Eric Ople
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals CorpfiledCriticalIdec Pharmaceuticals Corp
Publication of AU2001275437A1publicationCriticalpatent/AU2001275437A1/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU2001275437A2000-06-092001-06-11Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomasAbandonedAU2001275437A1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US21045100P2000-06-092000-06-09
US60/210,4512000-06-09
PCT/US2001/018700WO2001094641A2 (en)2000-06-092001-06-11Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas

Publications (1)

Publication NumberPublication Date
AU2001275437A1true AU2001275437A1 (en)2001-12-17

Family

ID=22782953

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2001275437AAbandonedAU2001275437A1 (en)2000-06-092001-06-11Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas

Country Status (3)

CountryLink
US (1)US20020051990A1 (en)
AU (1)AU2001275437A1 (en)
WO (1)WO2001094641A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7737255B1 (en)1998-09-022010-06-15Diadexus, Inc.Method of diagnosing, monitoring, staging, imaging and treating various cancers
US6962980B2 (en)1999-09-242005-11-08Corixa CorporationCompositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en)1998-12-172002-10-22Corixa CorporationCompositions and methods for therapy and diagnosis of ovarian cancer
US20020119158A1 (en)*1998-12-172002-08-29Corixa CorporationCompositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en)1998-12-172011-02-15Corixa CorporationOvarian cancer-associated antibodies and kits
US7232889B2 (en)*1999-03-082007-06-19Genentech, Inc.PRO300 antibodies
EP1892249A1 (en)*1999-09-012008-02-27Genentech, Inc.Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02012749A (en)*2000-06-302003-10-06Amgen IncB7-like molecules and uses thereof.
EP1445318A2 (en)*2000-08-242004-08-11Genetech, Inc.Compositions and methods for the diagnosis and treatment of tumor
GB0201808D0 (en)*2002-01-252002-03-13European Molecular Biology Lab EmblProtein
US20090110702A1 (en)2002-07-122009-04-30The Johns Hopkins UniversityMesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en)2002-07-122015-12-01The Johns Hopkins UniversityMesothelin vaccines and model systems
EP1575500A4 (en)*2002-07-122007-01-03Univ Johns Hopkins MESOTHELIN VACCINES AND MODEL SYSTEMS
EP3858387A1 (en)2003-11-062021-08-04Seagen Inc.Monomethylvaline compounds capable of conjugation to ligands
RU2404810C9 (en)2004-06-012015-06-20Дженентек, Инк.Conjugates antibody-medicinal agent and methods
WO2006034488A2 (en)2004-09-232006-03-30Genentech, Inc.Cysteine engineered antibodies and conjugates
US20100111856A1 (en)2004-09-232010-05-06Herman GillZirconium-radiolabeled, cysteine engineered antibody conjugates
US8759490B2 (en)2005-03-242014-06-24Millennium Pharamaceuticals, Inc.Antibodies that bind OV064 and methods of use therefor
EP3058955B1 (en)2005-03-242019-05-29Millennium Pharmaceuticals, Inc.Antibodies that bind ov064 and methods of use therefor
CA2630483C (en)2005-12-082015-05-19Medarex, Inc.Human monoclonal antibodies to o8e
EP2060583A1 (en)2007-10-232009-05-20Ganymed Pharmaceuticals AGIdentification of tumor-associated markers for diagnosis and therapy
JP2013504585A (en)2009-09-092013-02-07セントローズ, エルエルシー Extracellular targeted drug complex
EP2662095A1 (en)2010-04-152013-11-13Spirogen SàrlPyrrolobenzodiazepines and conjugates thereof
JP2013534520A (en)2010-06-082013-09-05ジェネンテック, インコーポレイテッド Cysteine engineered antibodies and conjugates
WO2012074757A1 (en)2010-11-172012-06-07Genentech, Inc.Alaninyl maytansinol antibody conjugates
CN103608684B (en)2011-05-122016-05-04基因泰克公司 A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
HUE025661T2 (en)2011-10-142016-04-28Medimmune LtdPyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en)2012-03-022013-09-06Genentech, Inc.Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
TR201808051T4 (en)2012-10-122018-06-21Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates.
DK2906251T3 (en)2012-10-122017-11-20Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
PT2766048E (en)2012-10-122015-02-25Spirogen Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES OF THE SAME
ES2660029T3 (en)2012-10-122018-03-20Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
WO2014057114A1 (en)2012-10-122014-04-17Adc Therapeutics SàrlPyrrolobenzodiazepine-anti-psma antibody conjugates
SMT201900017T1 (en)2012-10-122019-02-28Medimmune LtdPyrrolobenzodiazepine-antibody conjugates
DK2906253T3 (en)2012-10-122018-10-22Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
AU2013366493B2 (en)2012-12-212017-08-24Medimmune LimitedPyrrolobenzodiazepines and conjugates thereof
EA032986B1 (en)2012-12-212019-08-30Медимьюн ЛимитедPyrrolobenzodiazepines
CA2905181C (en)2013-03-132020-06-02Medimmune LimitedPyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
ES2731779T3 (en)2013-03-132019-11-19Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN105307685B (en)2013-03-132019-03-08麦迪穆有限责任公司Pyrrolobenzodiazepines Zhuo and its conjugate
WO2015023355A1 (en)2013-08-122015-02-19Genentech, Inc.1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052534A1 (en)2013-10-112015-04-16Spirogen SàrlPyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en)2013-10-112018-07-03Medimmune LimitedPyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en)2013-10-112015-04-16Spirogen SàrlPyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en)2013-10-112013-11-27Spirogen SarlPyrrolobenzodiazepines and conjugates thereof
WO2015095227A2 (en)2013-12-162015-06-25Genentech, Inc.Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016012410A2 (en)2013-12-162017-09-26Genentech Inc drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition
CA2929565A1 (en)2013-12-162015-06-25Genentech, Inc.1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN106687141A (en)2014-09-102017-05-17麦迪穆有限责任公司Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en)2014-09-122014-10-29Medimmune LtdPyrrolobenzodiazepines and conjugates thereof
BR112017003236A2 (en)2014-09-122017-11-28Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
CN106714844B (en)2014-09-122022-08-05基因泰克公司Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EA201790359A1 (en)2014-09-172017-08-31Дженентек Инк. Pyrrolobenzodiazepines and their conjugates associated with disulfide binding to antibodies
BR112017011111A2 (en)2014-11-252017-12-26Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en)2014-12-032017-07-25제넨테크, 인크.Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en)2015-04-152015-05-27Berkel Patricius H C Van And Howard Philip WSite-specific antibody-drug conjugates
GB201506411D0 (en)2015-04-152015-05-27Bergenbio AsHumanized anti-axl antibodies
MA43345A (en)2015-10-022018-08-08Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en)2015-10-162018-08-22Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en)2015-10-202018-08-29Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en)2016-01-262016-03-09Medimmune LtdPyrrolobenzodiazepines
GB201602359D0 (en)2016-02-102016-03-23Medimmune LtdPyrrolobenzodiazepine Conjugates
GB201602356D0 (en)2016-02-102016-03-23Medimmune LtdPyrrolobenzodiazepine Conjugates
US20170315132A1 (en)2016-03-252017-11-02Genentech, Inc.Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en)2016-04-292016-06-15Medimmune LtdPyrrolobenzodiazepine Conjugates
WO2017201449A1 (en)2016-05-202017-11-23Genentech, Inc.Protac antibody conjugates and methods of use
JP7022080B2 (en)2016-05-272022-02-17ジェネンテック, インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
CN109476648B (en)2016-06-062022-09-13豪夫迈·罗氏有限公司Sevelamer antibody-drug conjugates and methods of use
EP3496763A1 (en)2016-08-112019-06-19Genentech, Inc.Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en)2016-10-052022-04-08エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en)2016-10-142016-11-30Medimmune LtdPyrrolobenzodiazepine conjugates
GB201702031D0 (en)2017-02-082017-03-22Medlmmune LtdPyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (en)2017-02-082021-05-10Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
SI3612537T1 (en)2017-04-182022-10-28Medimmune LimitedPyrrolobenzodiazepine conjugates
US20200129637A1 (en)2017-04-202020-04-30Adc Therapeutics SaCombination therapy with an anti-axl antibody-drug conjugate
WO2018229222A1 (en)2017-06-142018-12-20Adc Therapeutics SaDosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (en)2017-08-182021-06-30메디뮨 리미티드 pyrrolobenzodiazepine conjugate
SG11202001907QA (en)2017-09-202020-04-29Ph Pharma Co LtdThailanstatin analogs
GB201803342D0 (en)2018-03-012018-04-18Medimmune LtdMethods
GB201806022D0 (en)2018-04-122018-05-30Medimmune LtdPyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en)2018-09-032018-10-17Femtogenix LtdCytotoxic agents
JP7708662B2 (en)2018-10-242025-07-15エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
CN113227119A (en)2018-12-102021-08-06基因泰克公司Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en)2019-01-292019-03-20Femtogenix LtdG-A Crosslinking cytotoxic agents
ES2967878T3 (en)2019-03-152024-05-06Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
GB2597532A (en)2020-07-282022-02-02Femtogenix LtdCytotoxic compounds
EP4426727A2 (en)2021-11-032024-09-11Hangzhou Dac Biotech Co., Ltd.Specific conjugation of an antibody
CN120417934A (en)2022-12-232025-08-01基因泰克公司 CEREBLON degrader conjugates and uses thereof
WO2024220546A2 (en)2023-04-172024-10-24Peak Bio, Inc.Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0906448B1 (en)*1996-04-052009-02-25Antonio GiordanoMethods for the diagnosis and prognosis of cancer
US7737255B1 (en)*1998-09-022010-06-15Diadexus, Inc.Method of diagnosing, monitoring, staging, imaging and treating various cancers
US6468546B1 (en)*1998-12-172002-10-22Corixa CorporationCompositions and methods for therapy and diagnosis of ovarian cancer
CA2392510A1 (en)*1999-11-302001-06-07Corixa CorporationCompositions and methods for therapy and diagnosis of breast cancer

Also Published As

Publication numberPublication date
WO2001094641A3 (en)2003-08-21
US20020051990A1 (en)2002-05-02
WO2001094641A2 (en)2001-12-13

Similar Documents

PublicationPublication DateTitle
AU2001275437A1 (en)Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
AU2003297300A1 (en)Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
AU2003222103A1 (en)Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
AU2001265296A1 (en)Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001231199A1 (en)Compositions and methods for the early diagnosis of ovarian cancer
AU3983201A (en)Compositions and methods for the early diagnosis of ovarian cancer
AU3491001A (en)Compositions and methods for the early diagnosis of ovarian cancer
AU2002315157A1 (en)Methods of screening for ligands of target molecules
AU2002251844A1 (en)Compositions and methods for the therapy and diagnosis of colon cancer
AU2002951346A0 (en)Diagnosis of ovarian cancer
AU6468998A (en)Compositions and method for the early diagnosis of ovarian cancer
AU2002254482A1 (en)Compositions and methods for the therapy and diagnosis of kidney cancer
EP1176964B8 (en)Uses of et743 for treating cancer
AU2002303219A1 (en)Compositions and methods for the therapy and diagnosis of cancer
AU2002239431A1 (en)Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002313426A1 (en)Tumor antigens for prevention and/or treatment of cancer
AU2002257458A1 (en)Mage-a1 peptides for treating or preventing cancer
AU7636800A (en)Improved ricin-like toxins for treatment of cancer
AU2001249317A1 (en)Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
AU2002330724A1 (en)Diagnosis, prevention and treatment of cancer
AU1700700A (en)Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
AU2002251367A1 (en)Proteins and genes for diagnosis and treatment of erbb2-related cancer
AU2001271284A1 (en)Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002363379A1 (en)Bidentate ligand for the telomerization of dienes
AU2001274946A1 (en)Compositions and methods for the therapy and diagnosis of ovarian cancer

[8]ページ先頭

©2009-2025 Movatter.jp